Prof Rajiv Jalan
@RajivJalan1
Followers
2K
Following
749
Media
46
Statuses
1K
Passionate about finding new treatments for liver disease to reduce deaths and improve QoL
London, UK
Joined October 2011
Looking forward. The votes about use of Rifaximin is split. Let’s analyse the existing data. See u all there
See you today 18:00 CET for an interactive EASL Studio on Rifaximin for Hepatic Encephalopathy, as we honour World Antimicrobial Awareness Week. 🔗 https://t.co/8g378Q0A0h
@DebbieShawcros1 @RajivJalan1 @DrVishalCPatel @JonelTrebicka
#LiverTwitter #LiverX
0
1
5
See you today 18:00 CET for an interactive EASL Studio on Rifaximin for Hepatic Encephalopathy, as we honour World Antimicrobial Awareness Week. 🔗 https://t.co/8g378Q0A0h
@DebbieShawcros1 @RajivJalan1 @DrVishalCPatel @JonelTrebicka
#LiverTwitter #LiverX
easl.eu
For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the...
0
3
6
It is wonderful to see the completion of recruitment of this hugely important study - the first randomised trial in the digital therapeutic study in the ArLD space. Thanks for @NIHR @alcochange @CyberLiver @SouthamptonCTU
It was great to part of @alcochange . Studies like these in patients with ArLD are not easy but are crucial! Massive congratulations to everyone involved and particularly thanks to the patients. Can’t wait for the results! @drgautammehta @RajivJalan1 @rajmookerjee @CyberLiver
0
2
3
It was great to part of @alcochange . Studies like these in patients with ArLD are not easy but are crucial! Massive congratulations to everyone involved and particularly thanks to the patients. Can’t wait for the results! @drgautammehta @RajivJalan1 @rajmookerjee @CyberLiver
A major step forward for digital liver care. The NHS-wide NIHR-funded clinical trial of AlcoChange DTx has reached a critical milestone: Last Patient Visit completed. This achievement paves the way for full data analysis, real-world adoption discussions. https://t.co/NVHFpFPOdw
1
3
8
Many congratulations. Your work has been of a seminal nature and the prize is well deserved
Delighted to take part in #ISHEN2025 Grateful for the opportunity to present our data, and truly honoured that one of the posters was recognised with the Best Poster Award by @ISHENliver Heartfelt thanks to Prof @RajivJalan1 and all my colleagues for making this possible.
1
1
4
Delighted to take part in #ISHEN2025 Grateful for the opportunity to present our data, and truly honoured that one of the posters was recognised with the Best Poster Award by @ISHENliver Heartfelt thanks to Prof @RajivJalan1 and all my colleagues for making this possible.
1
4
15
Thanks @BASLedu for inviting me to present my work on the novel DAS score which can predict 1️⃣ACLF 2️⃣ Mortality 3️⃣ Renal dysfunction Couldn’t resist plugging the next @uk_torch project as well! #EVADE
@rajmookerjee @RajivJalan1 @sheiybani @ChrisMysko @OTavabie @BSGTrainees
6
7
42
Hugely important paper - must read - provides the first comprehensive hypothesis of the clinicopathological correlates in cirrhosis phenotypes. ‘Not all cirrhosis is the same’ ‘No single approach works for all’ ‘drug development needs to be personalised and targeted. Opinions?
In patients w/ #Cirrhosis 📈#PortalHypertension #CSPH and 🔥#SystemicInflammation #SI coexist and drive both 🕸️#Liver disease progression and 🫀🫘🧠🫁 extrahepatic #organ pathology #Pathomechanistic #Phenotypes of #Cirrhosis 📕read @NatRevGastroHep 🔗 https://t.co/dyg6Sc4H2H
0
2
8
In patients w/ #Cirrhosis 📈#PortalHypertension #CSPH and 🔥#SystemicInflammation #SI coexist and drive both 🕸️#Liver disease progression and 🫀🫘🧠🫁 extrahepatic #organ pathology #Pathomechanistic #Phenotypes of #Cirrhosis 📕read @NatRevGastroHep 🔗 https://t.co/dyg6Sc4H2H
0
55
151
Agree - the bedside description could be based on a modified PIRO Predisposition - aetiology, first / further Injury: precipitant Response: Infection - inflammation - biomarkers Organ: NAD / AD e.g. P: alcoholic cirrhosis - first I: infection R: inflammation O: NAD-Ascites
@drnipunverma @EASLnews @INASL_Liver @APASLnews @BASLedu @RajivJalan1 @BavenoCoop @ProfPaoloAngeli @RoyAHep @AnandVKulkarni2 @AASLDtweets @ef_clif @ajay_duseja @drsuniltaneja @SahajRathi From a clinical point of view - since pts are also seen outside the academic hepatology bubble - a staging system must be simple & therapeutically relevant. ⏩clear "bedside definitions" ⏩use readily available liver disease severity scales @EASLnews 2024 i presented this slide
0
4
7
https://t.co/MoR7gDspDi Should cirrhosis decompensation be classified in phenotypes ? @EASLnews @INASL_Liver @APASLnews @BASLedu @RajivJalan1 @ReibergerThomas @BavenoCoop @ProfPaoloAngeli @RoyAHep @AnandVKulkarni2 @AASLDtweets @ef_clif @ajay_duseja @drsuniltaneja @SahajRathi
4
23
64
🚨 Excited to announce the next @uk_torch project #EVADE is now live! Please sign up below, we want as much representation as possible all over the UK 🇬🇧. https://t.co/vYxWKXabVq
@BSGTrainees @BASLedu @WAGE_media @OTavabie @jamesbmaurice @VSAthwal @sheiybani @ChrisMysko
0
6
9
What a fantastic initiative. Hugely important study - #basl ACLF SIG / @UK_CLIF can support in anyway you guys need…
Amazing stuff - moving to prospectively collected data demonstrates the evolution of @uk_torch - good luck with this project which is patient-centric and an area of need! An RCT for the next one maybe @RajivJalan1 @BASLedu @BritSocGastro @UK_CLIF @BSGTrainees
0
1
2
Amazing stuff - moving to prospectively collected data demonstrates the evolution of @uk_torch - good luck with this project which is patient-centric and an area of need! An RCT for the next one maybe @RajivJalan1 @BASLedu @BritSocGastro @UK_CLIF @BSGTrainees
We are officially live! #EVADE is running and we are encouraging sites to sign up! But what is EVADE and why should you even be interested in signing up? (1)
0
7
10
Hugely important paper - truly a collaborative efforts… illustrating more than the importance of biomarker based intervention - ACLF has similar characteristics both in the EAST and WEST. Clinically, Prognostically and Pathophysiologically!!
🚩NOT only a novel prognostic index in acutely decompensated cirrhosis.. 📍Our study identifying novel therapeutic targets in AD and ACLF @HepatologyPGI @ajay_duseja @drsuniltaneja in collaboration with @ucl @RajivJalan1 Berlin Cornelius 🎯 RIPK3 🎯 https://t.co/A08KieGavj
0
5
17
🚩NOT only a novel prognostic index in acutely decompensated cirrhosis.. 📍Our study identifying novel therapeutic targets in AD and ACLF @HepatologyPGI @ajay_duseja @drsuniltaneja in collaboration with @ucl @RajivJalan1 Berlin Cornelius 🎯 RIPK3 🎯 https://t.co/A08KieGavj
7
22
72
Many many congratulations- Prathiba-Parminder-Nipun team…. Class act
Honored to present my research as Presidential Poster at #INASL2025 and win 1st Prize 🏆. Grateful for the vision and mentorship of @drnipunverma, constant support of @ajay_duseja & @drsuniltaneja, my friend @pinderbrar888 and team @HepatologyPGI
2
1
5
Lovely to see HE in the model. The problem is with the use of West Haven criteria in diagnosing HE severity. Extremely low concordance and inter rater variability. We need a new test for HE. @ISHENliver
🙏 @AmJGastro for highlighting this! We need to do a better job advocating for our patients with #hepaticencephalopathy for transplant priority. @ISHENliver @AmCollegeGastro @VCU_Liver @AASLDtweets @ASTSChimera @EASLnews @APASLnews @ebtapper @RajivJalan1 @DebbieShawcros1
0
1
9
Deeply shocked and saddened at the loss of lives, many of them young students, in a tragic air crash in Dhaka. Our hearts go out to the bereaved families. We pray for the swift recovery of those injured. India stands in solidarity with Bangladesh and is ready to extend all
4K
5K
53K